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A B S T R A C T
Background
Asthma guidelines aim to guide health practitioners to optimise treatment for patients to minimise symptoms, improve or maintain
good lung function, and prevent acute exacerbations. The principle of asthma guidelines is based on a step-up or step-down regimen
of asthma medications to maximise health using minimum doses. Fractional exhaled nitric oxide (FeNO) is a marker of eosinophilic
inflammation and tailoring asthma medications in accordance to airway eosinophilic levels may improve asthma outcomes such as
indices of control or reduce exacerbations, or both.
Objectives
To evaluate the efficacy of tailoring asthma interventions based on fractional exhaled nitric oxide (FeNO), in comparison to not using
FeNO, that is, management based on clinical symptoms (with or without spirometry/peak flow) or asthma guidelines (or both), for
asthma-related outcomes in children.
Search methods
We searched the Cochrane Airways Group Specialised Register of Trials, the Cochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, Embase and reference lists of articles. The last searches were in June 2016.
Selection criteria
All randomised controlled trials (RCTs) comparing adjustment of asthma medications based on FeNO levels compared to those not
using FeNO, that is, management based on clinical symptoms or asthma guidelines (or both) involving children.
Data collection and analysis
We reviewed results of searches against predetermined criteria for inclusion. Two review authors independently selected relevant studies,
assessed trial quality and extracted data. We contacted study authors for further information with responses provided from three.
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Main results
The review included nine studies; these studies differed in a variety of ways including definition of asthma exacerbations, FeNO cut-
off levels used (12 parts per billion (ppb) to 30 ppb), the way in which FeNO was used to adjust therapy and duration of study (6 to
12 months). Of 1426 children randomised, 1329 completed the studies. The inclusion criteria for the participants in each study varied
but all had a diagnosis of asthma. There was a significant difference in the number of children having one or more asthma exacerbations
over the study period, they were significantly lower in the FeNO group in comparison to the control group (odds ratio (OR) 0.58,
95% confidence interval (CI) 0.45 to 0.75; 1279 participants; 8 studies). The number needed to treat for an additional beneficial
outcome (NNTB) over 52 weeks was 9 (95% CI 6 to 15). There was no difference between the groups when comparing exacerbation
rates (mean difference (MD) -0.37, 95% CI -0.8 to 0.06; 736 participants; 4 studies; I2 = 67%). The number of children in the FeNO
group requiring oral corticosteroid courses was lower in comparison to the children in the control group (OR 0.63, 95% CI 0.48
to 0.83; 1169 participants; 7 studies; I2 = 0%). There was no statistically significant difference between the groups for exacerbations
requiring hospitalisation (OR 0.75, 95% CI 0.41 to 1.36; 1110 participants; 6 studies; I2 = 0%). There were no significant differences
between the groups for any of the secondary outcomes (forced expiratory volume in one second (FEV1), FeNO levels, symptom scores
or inhaled corticosteroid doses at final visit). The included studies recorded no adverse events.
Three studies had inadequate blinding and were thus considered to have a high risk of bias. However, when these studies were removed
in subgroup analysis, the difference between the groups for the primary outcome (exacerbations) remained statistically significant. The
GRADE quality of the evidence ranged from moderate (for the outcome ’Number of participants who had one or more exacerbations
over the study period’) to very low (for the outcome ’Exacerbation rates’), based on lack of blinding, statistical heterogeneity and
imprecision.
Authors’ conclusions
In this updated review with five new included studies, tailoring asthmamedications based on FeNO levels (in comparison with primarily
guideline management) significantly decreased the number of children who had one or more exacerbations over the study period but
did not impact on the day-to-day clinical symptoms or inhaled corticosteroid doses. Therefore, the use of FeNO to guide asthma
therapy in children may be beneficial in a subset of children, it cannot be universally recommended for all children with asthma.
Further RCTs need to be conducted and these should encompass different asthma severities, different settings including primary care
and less affluent settings, and consider different FeNO cut-offs.
P L A I N L A N G U A G E S U M M A R Y
Can exhaled nitric oxide be used to adjust asthma medications in children with asthma?
Background
We investigated whether exhaled (breathing out) nitric oxide (a marker in the breath which can show a type of lung inflammation)
can be useful to adjust asthma medications in children with asthma instead of following the usual ways that asthma medications are
adjusted to get the best dose to control the asthma. Exhaled nitric oxide levels are easily obtained by getting the person to breathe into
a commercially available analyser.
Study characteristics
We included all randomised controlled trials that compared adjustment of asthma medications by either usual clinical care (control
group) versus using exhaled nitric oxide. The participants included in the trials had asthma diagnosed as per relevant asthma guidelines.
The evidence is current to June 2016 when the searches were last completed.
The review included nine studies (involving 1426 children) that varied in a several ways including length of the study, exhaled nitric
oxide cut-off levels used for altering medicines and the way each study defined flare-ups or attacks (called exacerbations). The studies
ranged from 6 to 12 months in length. The exhaled nitric oxide cut-off values used by the different studies as a basis for decreasing or
increasing medicines also varied.
The mean age of the participants ranged from 10 to 14 years old.
Key results
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In this review, we found that guiding asthma medicines based on exhaled nitric oxide (compared to a control group) was beneficial in
reducing the number of children who had at least one exacerbation during the study. In the control group where therapy was guided
according to clinical symptoms, 40 children out of 100 had at least one exacerbation over 48.5 weeks, compared to 28 out of 100
children where treatment was guided by exhaled nitric oxide. However, we found no difference between groups in other measures
of asthma severity that impact on day-to-day clinical symptoms or inhaled corticosteroid dose (medications used to control asthma).
Therefore, using exhaled nitric oxide levels to adjust asthma therapy may reduce the number of attacks that children with asthma have
but does not impact on the day-to-day symptoms.
Quality of the evidence
The level of evidence found ranged from moderate, when comparing the two groups for the number of children who had one or more
exacerbations, to very low when comparing the number of exacerbations.
3Exhaled nitric oxide levels to guide treatment for children with asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Tailoring asthma treatment using fractional exhaled nitric oxide vs clinical symptoms
Patient or population: children with asthma
Setting: outpat ient
Intervention: asthma treatment tailored on FeNO
Comparison: asthma treatment tailored on clinical symptoms
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with clinical
symptoms
Risk with asthma treat-
ment tailored on FeNO
Number of part icipants
who had ≥ 1 exacerba-
t ions over study period
(48.5 weeks)
40 per 100 28 per 100
(23 to 33)
OR 0.58
(0.45 to 0.75)
1279
(8 RCTs)
⊕⊕⊕©
Moderate1
-
Number of asthma ex-
acerbat ions per 52
weeks (exacerbat ion
rate)
The mean number of
asthma exacerbat ions
per 52 weeks (exacer-
bat ion rate) was 1.66
The mean number of
asthma exacerbat ions
per 52 weeks (exacer-
bat ion rate) in the inter-
vent ion group was 0.37
lower (0.8 lower to 0.06
higher)
MD -0.37 (-0.8 to 0.06) 736
(4 RCTs)
⊕©©©
Very low2
-
ICS dose at f inal
visit (budesonide equiv-
alent)
The mean ICS dose
at f inal visit (budes-
onide equivalent) was
483 µg/ day
The mean ICS dose at
f inal visit (budesonide
equivalent) in the in-
tervent ion group was
63.95 µg/ day higher
(51.89 lower to 179.79
higher)
- 317
(3 RCTs)
⊕⊕⊕©
Moderate3
-
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; FeNO: f ract ional exhaled nitric oxide; ICS: inhaled cort icosteroid; M D: mean dif ference; OR: odds rat io; RCT: randomised controlled trial
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Three studies carrying 23.7% of the analysis weight were at high risk of performance bias and detect ion bias due to the lack
of blinding (downgraded one level risk of bias) (de Jongste 2008; Verini 2010; Voorend-van Bergen 2015).
2One study carrying 11% of the analysis weight was open labelled which may have introduced detect ion bias (Verini 2010).
A random-ef fects sensit ivity analysis substant ially changed the result to MD -0.37 (95% CI -0.8 to 0.06). There was also
stat ist ical heterogeneity in the analysis (I2 = 67%, P = 0.03) (downgrade three levels for risk of bias, imprecision and
heterogeneity).
3One study carrying 47% of the analysis weight was single blinded and part icipants were aware of their allocat ion group
(downgraded one level for performance bias) (Voorend-van Bergen 2015).
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B A C K G R O U N D
Description of the condition
Asthma is one of the most common chronic diseases in children.
Acute attacks (exacerbations) are common in children with asthma
and some require more intensive treatment in hospital. Hospi-
talisations for asthma account for 12% to 21% (Anderson 2007;
Akinbami 2009) of hospitalisations worldwide (Gupta 2006).
Thus, prevention of exacerbations, particularly severe exacerba-
tions, is one goal of good asthma management. The second com-
ponent in asthma management is monitoring of asthma control
(by subjective and objective measures) (National Asthma Council
2014; BTS/SIGN 2016; GINA 2016). Subjective measures usu-
ally involve a series of questions used for clinical assessment, diary
cards and quality of life (QoL) questionnaires. Traditional objec-
tive methods include peak flow, spirometry and degree of airway
hyper-responsiveness (Zacharasiewicz 2005). Newer and arguably
more sensitive methods include measurement of airway inflam-
mation such as airway cellularity in induced sputum or fractional
exhaled nitric oxide (FeNO).
Airway inflammation associated with asthma can be eosinophilic
or neutrophilic (Douwes 2002). Arguably, asthma management is
best tailored in accordance to the type of airway inflammation, as
corticosteroids are more beneficial in eosinophilic inflammation
(Wardlaw 2000); inhaled corticosteroids (ICS) reduce exacerba-
tions and improve symptoms and asthma control (Wardlaw 2000).
There are several ways to quantify airway eosinophilic inflamma-
tion, such as determining the percentage of eosinophils in the spu-
tum and FeNO. FeNO correlates with other markers of asthma,
for example, eosinophilia in induced sputum (Jatakanon 1998),
and bronchial reactivity in non-steroid treated people (Dupont
1998).
Description of the intervention
The principle of asthma management is based on a step-up or
step-down regimen of asthma medications to reduce airway in-
flammation, control symptoms and reduce exacerbations. There-
fore, tailoring of asthma medications in accordance to levels re-
flective of airway eosinophilia may improve asthma control or re-
duce exacerbations, or both. Obtaining induced sputum samples
and sputum analysis is labour intensive and not widely available in
most routine clinical settings. Hypertonic saline, used to induce
sputum may also temporarily increase asthma symptoms (such as
wheeze, cough and chest tightness) and sputum is not always suc-
cessfully obtained in young children. Thus, measures of FeNO
confer some advantage over measurements of sputum eosinophils.
However, assessment of FeNO levels do not provide any data on
non-eosinophilic inflammation and the equipment required to
measure FeNO is relatively expensive.
FeNO levels can be measured using commercially available anal-
ysers. These analysers vary in several ways that include methods
of measurements (online or offline), complexity, setup, calibra-
tion procedures, sampling tube design, measuring chamber and
the way expiratory flow is controlled (Müller 2005). The station-
ary analysers measure FeNO by chemoluminescence whilst the
portable FeNO analysers measure FeNO using electrochemistry.
How the intervention might work
As FeNO is reflective of airway eosinophilia in some circum-
stances, FeNO can be considered as a biomarker. For asthma,
FeNO levels can potentially be used in children with asthma to:
• monitor airway eosinophilia;
• verify the adherence to ICS; and
• predict upcoming asthma exacerbations.
Reduction of airway inflammation improves symptoms and
asthma control (Wardlaw 2000). Hence, the use of FeNO levels to
tailor asthma medications in children with asthma may improve
asthma control or reduce exacerbations, or both.
Why it is important to do this review
A previous Cochrane Review included both adults and children
(Petsky 2009). Given the clinical heterogeneity between children
and adults with asthma, rather than update that review, we under-
took separate reviews for children and adults. This review focuses
on children and there is a similar systematic review that includes
only adults (Petsky 2016).
A systematic review evaluating the efficacy of tailoring asthma in-
terventions based on FeNO levels will be useful to guide clinical
practice in children with asthma. Using FeNO routinely in clinical
practice adds to the burden of asthma care and resource utilisation.
In addition, routine use of FeNO to guide use of asthma medica-
tions may improve asthma control and reduce exacerbations and
hospitalisations related to asthma.
O B J E C T I V E S
To evaluate the efficacy of tailoring asthma medications based on
fractional exhaled nitric oxide (FeNO), in comparison to not using
FeNO, that is, management based on clinical symptoms (with or
without spirometry/peak flow) or asthma guidelines (or both), for
asthma-related outcomes in children.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) comparing ad-
justment of asthma medications based on FeNO levels in com-
parison to those not using FeNO, that is, management based on
clinical symptoms (with or without spirometry/peak flow) or cur-
rent asthma guidelines, or both. We included studies reported as
full-text, abstract only, and unpublished data.
Types of participants
We included children/adolescents with a diagnosis of asthma ac-
cording to guideline-defined criteria.
We excluded participants with the following comorbidities/char-
acteristics: eosinophilic bronchitis, asthma related to an underly-
ing lung disease such as bronchiectasis and chronic obstructive
pulmonary disease or diagnostic categories such as ’cough variant
asthma’ and ’wheezy bronchitis’.
Types of interventions
We included RCTs comparing adjustment of asthma medications
based on FeNO levels versus control groups where FeNO is not
used to adjust asthma medications. Control group interventions
may have included use of clinical symptoms (with or without
spirometry/peak flow) to guide adjustment of asthmamedications.
Studies that included the use of other interventions were included
if all participants had equal access to such interventions. We in-
cluded trials of at least 12 weeks’ duration.
Types of outcome measures
Primary outcomes
• Asthma exacerbations during follow-up defined as:
◦ number of participants who had one or more
exacerbation over the study period;
◦ number of exacerbations per 52 weeks (exacerbation
rate);
◦ severe exacerbations requiring oral corticosteroids;
◦ severe exacerbation requiring hospitalisations.
Secondary outcomes
• Objective measurements of asthma control (forced
expiratory volume in one second (FEV1), peak flow, airway
hyper-responsiveness).
• FeNO level.
• Symptoms of asthma as reported in asthma QoL score.
• ICS dose at final visit.
Reporting one or more of the outcomes listed here was not an
inclusion criteria for this review.
Search methods for identification of studies
Electronic searches
We identified studies from the Cochrane Airways Group’s Spe-
cialised Register (CAGR), which is maintained by the Information
Specialist for the Group. The Register contains trial reports iden-
tified through systematic searches of bibliographic databases in-
cluding theCochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, Embase, CINAHL, AMED and PsycINFO,
and handsearching of respiratory journals and meeting abstracts
(see Appendix 1 for further details). We searched all records in the
CAGR using the search strategy in Appendix 2.
We also conducted a search of
ClinicalTrials.gov (www.ClinicalTrials.gov) and theWorld Health
Organization (WHO) trials portal (www.who.int/ictrp/en/). We
searched all databases from their inception to the present, and we
imposed no restriction on language of publication. All searches
were undertaken by the Cochrane Airways Group central team
(by Elizabeth Stovold) and the latest search was undertaken on 30
June 2016.
Searching other resources
We checked reference lists of all primary studies and review arti-
cles for additional references.We searched relevant manufacturers’
websites for trial information.
We searched for errata or retractions from included studies pub-
lished in full-text on PubMed (www.ncbi.nlm.nih.gov/pubmed),
and reported the date this was done within the review.
Data collection and analysis
Selection of studies
Two review authors (HP, KK) independently screened titles and
abstracts for inclusion of all the potential studies we identified
with the search and coded them as ’retrieve’ (eligible or potentially
eligible/unclear) or ’do not retrieve’. We then retrieved the full-
text study reports/publication and two review authors (HP, KK)
independently screened the full-text and identified studies for in-
clusion, and identified and recorded reasons for exclusion of the
ineligible studies.We planned to resolve any disagreement through
discussion or, if required, consult a third review author (AC). We
identified and excluded duplicates and collate multiple reports of
the same study so that each study, rather than each report, was the
unit of interest in the review. We recorded the selection process
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in sufficient detail to complete the PRISMA flow diagram and
Characteristics of excluded studies table.
Data extraction and management
We used a data collection form for study characteristics and out-
come data which was piloted on at least one study in the review.
One review author (HP) extracted study characteristics from in-
cluded studies. A second review author (KK) spot-checked study
characteristics for accuracy against the trial report. We then ex-
tracted the following study characteristics.
• Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals and date of study.
• Participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
• Interventions: intervention, comparison, concomitant
medications and excluded medications.
• Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
• Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (HP, KK) independently extracted outcome
data from included studies from current search. We noted in the
Characteristics of included studies table if outcome data were not
reported in a usable way. We resolved disagreements by consensus
or by involving a third review author (AC). One review author
(HP) transferred data into Review Manager 5 (RevMan 2014).
We double-checked that data were entered correctly by comparing
the data presented in the systematic review with the study reports.
Assessment of risk of bias in included studies
Two review authors (HP, KK) independently assessed risk of bias
for each new study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We planned to resolve any disagreements by discussion or by in-
volving another review author (AC). We assessed the risk of bias
according to the following domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We graded each potential source of bias as high, low or unclear
and provided a quote from the study report together with a jus-
tification for our judgement in the ’Risk of bias’ table. We then
summarised the risk of bias judgements across different studies for
each of the domains listed. We planned to blind separately for dif-
ferent key outcomes where necessary (e.g. for unblinded outcome
assessment, risk of bias for all-causemortalitymay be very different
from for a participant-reported pain scale).Where information on
risk of bias related to unpublished data or correspondence with a
trialist, we noted this in the ’Risk of bias’ table.
When considering treatment effects, we considered the risk of bias
for the studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol
and reported any deviations from it in the Differences between
protocol and review section of the systematic review.
Measures of treatment effect
Weanalysed dichotomous data as odds ratios (OR) and continuous
data as mean difference (MD) or standardised mean difference
(SMD) with 95% confidence intervals (CI). We then entered data
presented as a scale with a consistent direction of effect.
We undertook meta-analyses only where it was meaningful (i.e. if
the treatments, participants and the underlying clinical question
were similar enough for pooling to make sense).
We narratively described skewed data reported as medians and
interquartile ranges.
Where multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) were combined in the
same meta-analysis, we halved the control group to avoid double-
counting.
Unit of analysis issues
For dichotomous data, we reported the proportion of participants
contributing to each outcome in comparison with the total num-
ber randomised. For rate ratios of common events whereby one
participant may have more than one event, we used generic in-
verse variance (GIV) analysis. The rate ratios were taken from the
published papers and the standard errors calculated from CIs or
P values published in the papers. We had planned for cross-over
studies, to calculate themean treatment differences from raw data,
and variances extracted or imputed and entered as a fixed-effect
(GIV) outcome, to provide summary weighted differences and
95% CIs.
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and obtain missing numerical outcome data where
possible (e.g. when a study was identified as abstract only). Where
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this was not possible, and the missing data were thought to intro-
duce serious bias, we explored the impact of including such studies
in the overall assessment of results by a sensitivity analysis.
Assessment of heterogeneity
We described any heterogeneity between the study results and
tested it to see if it reached statistical significance using a Chi2 test.
We planned to include the 95% CI estimated using a random-
effects model whenever there were concerns about statistical het-
erogeneity. Heterogeneity was considered significant when the P
value is less than 0.10 (Higgins 2011).We then used the I2 statistic
to measure heterogeneity among the trials in each analysis. If we
identified substantial heterogeneity, we reported it and explored
possible causes by prespecified subgroup analysis.
Assessment of reporting biases
We were unable to pool more than 10 trials, so did not create
and examine a funnel plot to explore possible small-study and
publication biases.
Data synthesis
We included the results from studies that met the inclusion criteria
and reported any of the outcomes of interest in the subsequent
meta-analyses. We calculated the summary weighted RR and 95%
CI (fixed-effect model) using Review Manager 5 (RevMan 2014).
For rate ratios of common events whereby one participant may
havemore than one event, we used GIV. The rate ratios were taken
from the published papers and the standard errors calculated from
CIs or P values published in the papers. For cross-over studies, we
planned to calculate themean treatment differences from rawdata,
and extract or impute variances and enter them as fixed-effect GIV
outcomes, to provide summary weighted differences and 95% CI.
Numbers needed to treat were calculated from the pooled OR and
its 95% CI applied to a specified baseline risk using an online
calculator (Cates 2008). The outcome indices were assumed to be
normally distributed continuous variables so theMDs in outcomes
could be estimated. If studies reported outcomes using different
measurement scales, we estimated the SMD.
’Summary of findings’ table
We created a ’Summary of findings’ table using the following out-
comes:
• number of participants who had one or more exacerbations
over the study period;
• number of asthma exacerbations per 52 weeks,
• ICS dose at final visit.
The ’Summary of findings’ table in the previous combined review
(Petsky 2009) was amended to reflect new data and restricted to
the inclusion criteria. We used the five GRADE considerations
(study limitations, consistency of effect, imprecision, indirectness
and publication bias) to assess the quality of a body of evidence
as it relates to the studies which contribute data to the meta-
analyses for the prespecified outcomes. We then used methods
and recommendations described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011) using GRADEpro software (GRADEpro GDT
2015). We justified all decisions to downgrade or upgrade the
quality of studies using footnotes and we made comments to aid
reader’s understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analyses:
• basis for adjustment of ICS in the control group (guideline
driven monitoring versus non-guideline driven);
• use of spirometry or peak flow as an adjunctive monitoring
tool for adjustment of medications versus non-use of spirometry
or peak flow;
• baseline ICS dose at commencement of intervention (low-
medium (< 800 µg/day of budesonide equivalent) versus high
dose (800 µg/day or more of budesonide equivalent);
• FeNO cut-offs for adjustment of medications (20 parts per
billion (ppb) or less versus more than 20 ppb);
• FeNO cut-offs, based on presence of atopy.
Sensitivity analysis
We carried out the following sensitivity analyses.
• Sensitivity analysis excluding studies with a high risk of bias
based on the ’Risk of bias’ assessment. We removed studies that
did not have adequate allocation concealment and sequence
generation.
• Variation in the inclusion criteria. We removed studies that
included children not receiving ICS at recruitment.
• Differences in the medications used in the intervention and
comparison group. We removed studies that adjusted
medications only for one arm.
• Analysis comparing the random-effects model to a fixed-
effect model.
• Analysis by ’strategy received’. We removed studies with
hierarchy management protocols that only considered use of
steroids for each step (i.e. without consideration for using
montelukast or long-acting beta-agonist (LABA), or both, at any
point).
R E S U L T S
Description of studies
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See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies tables.
Results of the search
From the searches, the CAGR identified 1084 potentially relevant
titles (Figure 1). We identified an additional 129 titles through
searches of ClinicalTrials.gov (www.ClinicalTrials.gov) and the
WHO trials portal (www.who.int/ictrp/en/). After assessing the
abstracts, we obtained 30 papers for consideration after removing
duplicates. We excluded 14 papers due to non-randomisation or
treatment not being based on FeNO. Of the potential 16 papers,
nine included children or adolescents and the remaining seven
were based on adults, which are presented in a separate Cochrane
Review (Petsky 2016).
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Figure 1. Prisma flow diagram.
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Included studies
The review included nine studies (see Characteristics of included
studies). The nine studies involved 1426 randomised participants
with 1329 completing the trials (Pijnenburg 2005; Fritsch 2006;
Szefler 2008; de Jongste 2008; Verini 2010; Pike 2013; Peirsman
2014; Petsky 2015; Voorend-van Bergen 2015). Of these nine
studies, five were new (i.e. were not in the previous (Petsky 2009)
review).
Study design
All nine studies were parallel-group studies. Five were multicentre
studies (Szefler 2008; de Jongste 2008; Pike 2013; Peirsman 2014;
Voorend-van Bergen 2015), one was dual centre (Petsky 2015),
and three were single-centre studies (Pijnenburg 2005; Fritsch
2006; Verini 2010).
One study used a three-arm strategy to adjust ICS (Voorend-van
Bergen 2015). The strategy arms were: web group, where treat-
ment was adjusted monthly based on the web-based Asthma Con-
trol Test (ACT) score; FeNO group, where treatment was adjusted
according to FeNO and ACT score at four-monthly clinic visits;
or standard care, where treatment was adjusted according to the
ACT score during clinic visits. For this review, we considered the
FeNO with ACT score strategy arm as the intervention group and
the standard care strategy as the control group.
Of the nine studies; four were double blind (Pijnenburg 2005;
Szefler 2008; Pike 2013; Petsky 2015), three were single blind
(Fritsch 2006; Peirsman 2014; Voorend-van Bergen 2015), and
two had no blinding (de Jongste 2008; Verini 2010).
The study duration varied ranging from 6 to 12 months (Table
1). Each study defined exacerbations differently (Table 1).
Participants
The nine studies had different inclusion criteria for the partici-
pants. All studies included participants with asthma which was
defined as per current guidelines.
Fractional exhaled nitric oxide strategy
The intervention arm in all nine studies, although primarily based
on FeNO level, differed in the cut-off for FeNO for change in
therapy. Petsky 2015 was the only study which utilised different
cut-offs for the presence of atopy.
The FeNO cut-offs used for the studies are presented in Table 1.
Control group
Five of the nine studies utilised existing asthma guidelines to ad-
just treatment in the control group (Fritsch 2006; Szefler 2008;
Verini 2010; Pike 2013; Peirsman 2014). Three studies used par-
ticipant-reported symptoms (Pijnenburg 2005; de Jongste 2008;
Petsky 2015), and one utilised the Asthma Control Questionnaire
(ACQ) (Voorend-van Bergen 2015). The control group strategies
are described in Table 1.
Outcomes
The primary outcomes of the studies also varied. Three stud-
ies used symptom-free days (de Jongste 2008; Peirsman 2014;
Voorend-van Bergen 2015), three studies used asthma exacerba-
tions (Verini 2010; Pike 2013; Petsky 2015), three studies included
ICS cumulative doses (Pijnenburg 2005; Verini 2010; Pike 2013),
one study used number of days with symptoms (Szefler 2008),
and another used FEV1 (Fritsch 2006). The definitions of exacer-
bations were different among the studies (Table 1).
The secondary outcomes also varied between the studies. Four
studies included asthma exacerbations (Fritsch 2006; Pike 2013;
Peirsman 2014; Voorend-van Bergen 2015), four studies used dose
of ICS (Fritsch 2006; de Jongste 2008; Petsky 2015; Voorend-van
Bergen 2015), three studies included spirometry (de Jongste 2008;
Petsky 2015; Voorend-van Bergen 2015), and Petsky 2015 and de
Jongste 2008 used asthma QoL questionnaires.
We contacted study authors to request further data, or data that
could be included in the meta-analysis; three study authors pro-
vided data (Pike 2013; Petsky 2015; Voorend-van Bergen 2015).
The study characteristics are described in the Characteristics of
included studies table.
Excluded studies
We recorded the reasons for excluding the 20 studies in the
Characteristics of excluded studies table. The most common rea-
sons for exclusion were: not an RCT (seven studies), treatment
not adjusted according to FeNO (six studies), and population was
not children or adolescents (seven studies). One further study was
found in abstract form only (Duong-Quy 2015). We contacted
this study author in January 2016 and they confirmed that the pa-
per is in preparation, therefore this study was judged to be ongoing
and will be included in the next update (Duong-Quy 2015).
Risk of bias in included studies
The full details of risk of bias judgements is described under the
’Risk of Bias’ section in the Characteristics of included studies
table and is summarised in Figure 2. Overall, the methodological
quality of the included studies was good.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Four studies described generation of randomisation sequence (
Szefler 2008; Pike 2013; Petsky 2015; Voorend-van Bergen 2015),
and it was unclear in five studies (Pijnenburg 2005; Fritsch 2006;
de Jongste 2008; Verini 2010; Peirsman 2014). The method of
allocation concealment was adequate in four studies (Szefler 2008;
Pike 2013; Peirsman 2014; Petsky 2015), and unclear in five (
Pijnenburg 2005; Fritsch 2006; de Jongste 2008; Verini 2010;
Voorend-van Bergen 2015).
Blinding
Risk associated with participant blinding was low when the blind-
ing of the assessors was reported based on information provided by
authors of the studies. These included comments from the studies
such as “a third party provided advice on treatment decisions” and
“both arms of the study received the same follow-up including
measurements and tests”.
Risk of detection bias due to inadequate blinding of outcome as-
sessors was high in three studies (de Jongste 2008; Verini 2010;
Voorend-van Bergen 2015), and unclear in one study (Fritsch
2006), as there was not enough information in the published arti-
cle. Five studies were at low risk of bias (Pijnenburg 2005; Szefler
2008; Pike 2013; Peirsman 2014; Petsky 2015).
Incomplete outcome data
Five studies were at low risk of attrition bias (Szefler 2008; de
Jongste 2008; Peirsman 2014; Petsky 2015; Voorend-van Bergen
2015). Three studies were at high risk of attrition bias as they re-
ported unbalanced dropout rates (Fritsch 2006; Pijnenburg 2005;
Pike 2013). Verini 2010 did not report on dropouts and was there-
fore judged at unclear risk of attrition bias.
Selective reporting
Reporting bias was low in two studies with all outcomes being re-
ported (Peirsman 2014; Voorend-van Bergen 2015). Three studies
were at unclear risk of reporting bias as there was inadequate in-
formation in the published articles (Pijnenburg 2005; de Jongste
2008; Pike 2013). Four studies were at high risk of reporting bias
as some of the secondary outcomes were not reported or incorrect
analyses methods were used (Fritsch 2006; Szefler 2008; Verini
2010; Petsky 2015).
Other potential sources of bias
Another source of bias was the success of obtaining FeNO levels at
each visit according to current guidelines. Five studies did not re-
port the success of obtaining FeNOat each time point (Pijnenburg
2005; Szefler 2008; Verini 2010; Peirsman 2014; Voorend-van
Bergen 2015). One study reported that they successfully obtained
FeNO at each visit (Petsky 2015). Two studies were at high risk as
they reported technical problems with the FeNO analysers includ-
ing 11 out of 77 analysers showing drift in calibration after the
study (Fritsch 2006; de Jongste 2008). Pike 2013 was at high risk
as they reported not following current guidelines by only doing a
single measurement of FeNO at each visit.
Effects of interventions
See: Summary of findings for the main comparison Tailoring
asthma treatment using fractional exhaled nitric oxide versus
clinical symptoms
See Summary of findings for the main comparison for the main
comparisons.
Primary outcome: asthma exacerbations
Three studies used asthma exacerbations as their primary outcome
but the definition differed among the studies (described in Table
1), as did the way the outcomewasmeasured and presented (Verini
2010; Pike 2013; Petsky 2015). Three studies reported a reduction
in asthma exacerbations in the intervention arm compared to the
control arm (Verini 2010; Peirsman 2014; Petsky 2015). For the
various types of exacerbations, we combined data into the meta-
analysis, as described below.
1.1 Number of participants who had one or more
exacerbations over the study period
See Analysis 1.1.
Combined data from eight studies showed that the number of
participants experiencing an exacerbation was significantly lower
(P = 0.0002) in the FeNO group compared to the control (clinical
symptom) group over the study period (OR 0.58, 95% CI 0.45
to 0.75; 1279 participants; 8 studies; I2 = 7%) (de Jongste 2008;
Peirsman 2014; Petsky 2015; Pijnenburg 2005; Pike 2013; Szefler
2008; Verini 2010; Voorend-van Bergen 2015). There was some
statistical heterogeneity among the studies but it was not signif-
icant (I2 = 7%). In the control group where therapy was guided
according to clinical symptoms, 40 children out of 100 had at least
one exacerbation over 48.5 weeks, compared to 28 (95% CI 23 to
33) out of 100 for those where treatment was guided by FeNO.
The number needed to treat to show an additional beneficial out-
come (NNTB) over 52 weeks was 9 (95% CI 6 to 15) (Figure 3).
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Figure 3. In the control group, 40 children out of 100 had exacerbations over one year, compared to 28 (95%
confidence interval (CI) 23 to 33) out of 100 for the active treatment group. Number needed to treat for one
additional beneficial outcome = 9 (95% CI 6 to 15).
1.2 Number of exacerbations per 52 weeks (exacerbation
rates)
See Analysis 1.2.
Combined data from four studies for the outcome of exacerbation
rate (over 52 weeks) found no differences between the groups (P
= 0.09) (MD -0.37, 95% CI -0.80 to 0.06; 736 participants; 4
studies) (Szefler 2008; Verini 2010; Pike 2013; Petsky 2015). As
there was statistical heterogeneity among the studies (I2 = 67%, P
= 0.03), we used a random-effects analysis. The statistical hetero-
geneity could be accounted for by the skew in some of the studies
data. The rate of exacerbation over the 52 weeks in the control
group ranged from 0.78 to 3.2.
1.3 Number of participants who had severe exacerbations
requiring hospitalisation
See Analysis 1.3.
Five studies reported hospitalisations due to worsening of asthma
symptoms (Fritsch 2006; Szefler 2008; Pike 2013; Peirsman 2014;
Voorend-van Bergen 2015), and another study reported that no
participants were hospitalised (Petsky 2015). In the meta-analysis,
there was no significant difference (P = 0.37) between groups;
20 children in the FeNO group versus 26 in the control group
required hospitalisation (OR 0.75, 95% CI 0.41 to 1.36; 1110
participants; 6 studies; I2 = 0%).
1.4 Number of participants who had severe exacerbations
requiring rescue oral corticosteroids
See Analysis 1.4.
Seven studies reported using rescue oral corticosteroids (de Jongste
2008; Fritsch 2006; Peirsman 2014; Petsky 2015; Pijnenburg
2005; Szefler 2008; Voorend-van Bergen 2015). The meta-analy-
sis showed a significantly fewer children (P = 0.001) in the FeNO
group required rescue oral corticosteroids compared to the con-
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trol group (OR 0.63, 95% CI 0.48 to 0.83; 1169 participants; 7
studies; I2 = 0%).
Secondary outcomes
1.5 FEV1% predicted at final visit
See Analysis 1.5.
We combined the final visit FEV1% predicted from seven stud-
ies in a meta-analysis and we found no significant difference be-
tween the groups (P = 0.12; MD 1.0, 95% CI -0.07 to 2.07;
1181 participants; 7 studies; I2 = 0%) (de Jongste 2008; Peirsman
2014; Petsky 2015; Pijnenburg 2005; Pike 2013; Szefler 2008;
Voorend-van Bergen 2015). The two remaining studies reported
no significant difference between the two groups, but as details
were not provided, we could not include the data in the meta-
analysis (Fritsch 2006; Verini 2010).
1.6 FeNO geometric mean level at final visit
See Analysis 1.6.
We combined the final visit’s FeNO geometric mean (GM) from
three studies in ameta-analysis (de Jongste 2008; Pijnenburg 2005;
Voorend-van Bergen 2015). The data were heavily skewed and
ratio ofGMwas themost appropriate analysis to use. There was no
significant difference between the groups (GM 0.98, 95%CI 0.87
to 1.11; 356 participants; 3 studies; I2 = 69%). The remaining six
studies could not be included in themeta-analysis but reported that
there was no significant difference between the groups at the final
visit (Fritsch 2006; Peirsman 2014; Petsky 2015; Pike 2013; Szefler
2008; Verini 2010). Fritsch 2006, and Peirsman 2014 reported
that there was a decreased trend in FeNO levels for the FeNO
group at the final visit but this was not significant.
1.7 Symptom score: Asthma Control Test
See Analysis 1.7.
Two studies reported ACT results; the meta-analysis showed no
significant difference between groups (MD 0.14, 95% CI -0.18
to 0.47; 724 participants; 2 studies; I2 = 62%) (Szefler 2008;
Voorend-van Bergen 2015).
1.8 Symptom score as per Paediatric Asthma Caregiver’s
Quality of Life Questionnaire (PACQLQ)
See Analysis 1.8.
Combined data from three studies found no significant difference
between groups for the PACQLQ (MD 0.09, 95% CI -0.08 to
0.27; 380 participants; 3 studies; I2 = 0%) (de Jongste 2008; Petsky
2015; Voorend-van Bergen 2015).
1.9 Inhaled corticosteroid dose at final visit (budesonide
equivalent in micrograms per day)
See Analysis 1.9.
Three studies reported final ICS doses that could be included in
a meta-analysis; there was no significant difference between the
groups (MD 63.95 µg/day, 95% CI -51.89 to 179.79; 317 partic-
ipants; 3 studies; I2 = 40%) (Pike 2013; Petsky 2015; Voorend-van
Bergen 2015). Using a random-effects model, the difference be-
tween the groups remained nonsignificant (MD 65.88 µg/day,
95% CI -86.71 to 218.47).
Four studies reported that there was no difference in daily ICS
doses between the groups at the final visit (Pijnenburg 2005; de
Jongste 2008; Verini 2010; Peirsman 2014). The remaining two
studies reported that the control group had lower doses of ICS at
the end of the study (Fritsch 2006; Szefler 2008).
1.10 Cost effectiveness of the intervention
One study (Voorend-van Bergen 2015) published a separate paper
(Beerthuizen 2016) assessed the cost of the strategies in their three-
armed trial (standard care, web-based strategy and FeNO-based).
They reported no significant difference in costs or quality-adjusted
life years between the groups. Theweb-based strategy (this armnot
included in this systematic review) was 77% more cost effective
from a healthcare perspective, whereas the FeNO-based strategy
had an 83% chance of being most cost effective from a societal
perspective.
Subgroup analysis and investigation of heterogeneity
1. Based on adjustment of inhaled corticosteroid in the
control group (guideline-driven versus others)
When testing for subgroup differences there was no significant
difference between the subgroups for either exacerbation outcome
(Analysis 1.10; Analysis 1.11).
Four of the studies utilised asthma guidelines as the basis of adjust-
ing medications in the control group (Szefler 2008; Verini 2010;
Pike 2013; Peirsman 2014). In this subgroup, for the primary out-
come of number of participants with one or more exacerbations,
the significant difference between the groups was still present,
favouring the FeNO group (OR 0.67, 95% CI 0.51 to 0.90). In
the studies that used other methods for adjusting medications as
the control group, also fewer children in the FeNO group had
exacerbations compared to the control group (OR 0.55, 95% CI
0.34 to 0.90). Likewise, there was a significant difference between
the groups for the outcome of exacerbation rates for the studies
where the control groups’ management was guideline-driven (MD
-0.27, 95% CI -0.49 to -0.06), as well as for the studies where the
control groups’ management was not guideline-driven (i.e. other)
16Exhaled nitric oxide levels to guide treatment for children with asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(MD -0.39, 95% CI -0.84 to 0.06). However, there was signifi-
cant statistical heterogeneity in this subgroup analyses when con-
sidering only the guideline-driven studies.
2. Use of spirometry or peak flow as an adjunctive
monitoring tool for adjustment of medications (versus non-
use of spirometry or peak flow)
Five studies utilised spirometry when adjusting medications in the
control group (Fritsch 2006; Szefler 2008; Verini 2010; Pike 2013;
Peirsman 2014); however, spirometry was not the sole measure-
ment for adjusting the medications, therefore this subgroup anal-
ysis could not be done. As per Table 1, all five studies used asthma
guidelines which included participant-reported symptoms, SABA
use and spirometry.
3. Baseline inhaled corticosteroid dose at commencement
of intervention (low-medium (< 800 µg/day of budesonide
equivalent) versus high dose (800 µg/day or more of
budesonide equivalent))
In six studies, the median ICS dose at baseline was less than
800 µg/day of budesonide equivalent (Pijnenburg 2005; Fritsch
2006; de Jongste 2008; Peirsman 2014; Petsky 2015; Voorend-van
Bergen 2015). However, none of the studies analysed their data
based on baseline ICS dose, hence this subgroup analysis could
not be done.
One study did not provide the daily ICS dosage in micrograms
per day so could not be included in this subgroup analysis (Verini
2010).
4. Fractional exhaled nitric oxide cut-offs for adjustment of
medications (20 ppb or less versus more than 20 ppb)
Three studies adjusted medications when the FeNO levels were
20 ppb or less as described in Table 1 (Fritsch 2006; Verini 2010;
Petsky 2015).When considering this in the subgroup analysis, the
results were similar to the main analyses.
By removing Pijnenburg 2005; Szefler 2008; de Jongste 2008; Pike
2013; Peirsman 2014; and Voorend-van Bergen 2015 (in Analysis
1.1) who adjusted medications when FeNO was greater than 20
ppb from the first outcome (number of participants who had one
or more exacerbations), the difference between groups remained
statistically different (P = 0.0007; OR 0.25, 95% CI 0.11 to 0.56;
I2 = 0%). Likewise, for the second outcome of exacerbation rates,
by removing Szefler 2008 and Pike 2013, the difference between
groups favoured the FeNO group (MD -0.63, 95% CI -0.98 to -
0.27; I2 = 65%).
5. Fractional exhaled nitric oxide cut-offs, based on presence
of atopy
Only one study considered atopy in their algorithm for FeNO
levels (Petsky 2015). Removing this study from the primary out-
comes of exacerbations, the meta-analyses results still significantly
favoured the FeNO group. For the first outcome, the number of
participants who had more than one exacerbation over the study
period, the difference between groups remained statistically dif-
ferent (OR 0.65, 95% CI 0.51 to 0.85; I2 = 9%). Likewise, for the
exacerbation rates, removing Petsky 2015 from the FeNO group
also resulted in a statistically difference between groups (MD -
0.27, 95% CI -0.49 to -0.06; I2 = 77%).
Sensitivity analyses
1. Excluding studies with a high risk of bias based on the
’Risk of bias’ assessment
There were three included studies which had no blinding (de
Jongste 2008; Verini 2010; Voorend-van Bergen 2015). However,
when the data from these studies was removed it did not alter the
results of the primary outcome (exacerbations) found in the main
analyses. Summary data for the number of participants who had
one or more exacerbations over the study period (OR 0.67, 95%
CI 0.50 to 0.89; 887 participants; 5 studies) and exacerbation rate
(MD -0.2, 95% CI -0.41 to 0.0; 672 participants; 3 studies) still
favoured the FeNO group.
2. Variation in the inclusion criteria
Three studies reported that not all included children were receiv-
ing ICS at recruitment (Fritsch 2006; Verini 2010; Pike 2013).
Removing Verini 2010 and Pike 2013 from the analyses resulted
in similar results (i.e. outcomes favoured the FeNO group); the
number of participants who had one or more exacerbations (OR
0.64, 95% CI 0.49 to 0.84; 1125 participants; 6 studies). Like-
wise, the group differences for exacerbation rate remained signifi-
cantly different between groups favouring the FeNO group (MD
-0.23, 95% CI -0.43 to -0.02; 609 participants; 2 studies).
3. Differences in the medications used in the intervention
and comparison group
There were no studies that adjusted medications only for one arm,
therefore this planned sensitivity analysis was not undertaken.
4. Analysis using random-effects model
Using a random-effectsmodel did not change the significant group
differences between the groups (i.e. favoured the FeNO group),
in the number of participants who had one or more exacerbations
over the study period (OR 0.58, 95% CI 0.42 to 0.81; 1279
participants; 8 studies).
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Due to the high levels of heterogeneity (I2 = 67%), we used a
random-effects model to analyse number of exacerbations per 52
weeks, which resulted in a non-statistically significant estimate
favouring the FeNO group (MD -0.37, 95% CI -0.80 to 0.06;
736 participants; 4 studies). There was a significant difference
between groups when a fixed-effectmodel was applied (MD -0.30,
95% CI -0.49 to -0.10; 736 participants; 4 studies), but this latter
model is considered less appropriate in the context of high levels
of heterogeneity.
5. Analysis by ’strategy received’
One study used a hierarchy management protocol that was based
solely on the use of steroids for each step (i.e. without consid-
eration for using montelukast or LABA, or both, at any point)
(Pijnenburg 2005). Removing this study from the analyses did not
alter the significant group differences found in the main analyses.
The number of participants who had one or more exacerbations
over the study period favoured the FeNO arm (OR 0.62, 95% CI
0.48 to 0.8; 1190 participants; 7 studies).
D I S C U S S I O N
Summary of main results
The nine RCTs included in this review involved 1426 children
(1329 completed). The studies varied in many aspects including
the FeNO levels used, the algorithms, study duration and the
strategy used for the control arm.
All studies reported our review’s primary outcome (exacerbation).
However, the studies defined exacerbation in various ways. Data
from eight studies were combined for the meta-analysis of the
outcome, number of participants having one or more asthma ex-
acerbation. Significantly fewer children in the FeNO group had
exacerbations compared to the control group (OR 0.58, 95% CI
0.45 to 0.75). The NNTB over 52 weeks was 9 (95% CI 6 to 15).
There was no difference between the groups when comparing the
exacerbation rates (MD -0.37, 95% CI -0.8 to 0.06). When com-
bining seven studies, we found that fewer children in the FeNO
group required rescue courses of oral corticosteroids compared to
controls (OR 0.63, 95% CI 0.48 to 0.83). However, there was no
difference between the groups for severe exacerbations requiring
hospitalisation (OR 0.75, 95% CI 0.41 to 1.4). There were 20
hospitalisations in the FeNO group versus 26 in the control group.
In the subgroup analyses, the main analyses for the primary out-
come of exacerbations continued to favour the FeNO group when
restricting the analysis to the studies that utilised guidelines for
the control group (number of participants who had one or more
exacerbation: OR 0.67, 95% CI 0.51 to 0.90; exacerbation rate:
MD -0.27, 95% CI-0.49 to -0.06). There was no statistical dif-
ference between the subgroups in these analyses.
In the sensitivity analyses, the only changes seen in the primary
outcome analyses was when we applied the fixed-effect analysis to
the outcome exacerbation rates per 52 weeks. As per our protocol,
we chose to perform our primary analysis of this outcome with a
random-effects model, which is more appropriate in the context
of the substantial heterogeneity detected (I2 = 67%). Unlike the
random-effects model, the fixed-effect model resulted in a statisti-
cally significant estimate favouring the FeNO group (MD -0.30,
95% CI -0.49 to -0.10; 736 participants; 4 studies). However, the
number of participants who had one or more exacerbation over
the study period (analysed primarily with a fixed-effect model)
remained favourable towards the FeNO group when a sensitivity
analysis was performed with a random-effects model (OR 0.58,
95% CI 0.42 to 0.81).
In contrast to the data relating to exacerbations, there was no
significant difference between groups for any of the secondary
outcomes (FEV1, FeNO levels, symptom scores or final ICS dose).
Overall completeness and applicability of
evidence
This review included nine studies but not all studies could be in-
cluded in every outcome for the meta-analyses. The meta-analyses
consisted of data from two to eight studies. The number of chil-
dren for the various outcomes ranged from 317 (outcome: ICS
dose at final visit) to 1297 (outcome: Number of participants who
had one or more exacerbations over the study period). Therefore,
the completeness of the review was limited by the available data,
although we contacted the authors of the included studies for ad-
ditional data.
Two of the primary outcomes (’Number of participants who had
one or more exacerbations over the study period’ and ’Severe exac-
erbations requiring oral corticosteroids’) favoured the FeNO arm,
however there was no significant group differences for ’Exacerba-
tion rate’, ’Severe exacerbations requiring hospitalisation’ or for
any secondary outcomes (symptom scores, FeNO at end of study,
FEV1 at end of study or ICS doses). There were no changes in the
primary outcomes when subgroup analysis was undertaken with
FeNO group being favoured in three out of four of the primary
analyses.
All nine studies were hospital-based and undertaken since the early
2000’s in affluent countries; three in the Netherlands (Pijnenburg
2005; de Jongste 2008; Voorend-van Bergen 2015), one in Austria
(Fritsch 2006), one in Belgium (Peirsman 2014), one in Australia
(Petsky 2015), one in the UK (Pike 2013), one in the USA (Szefler
2008), and one in Italy (Verini 2010). There is a gap of evidence
from the low-income countries, therefore limiting this review’s
findings in resource-poor settings. Likewise, none of the included
studies were from a primary care setting, therefore restricting in-
terpretation of these findings to hospital settings only. As children
looked after in primary care are likely to have less severe asthma
(compared to children looked after in hospitals).
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Guidelines on the interpretation of FeNO levels suggest using a
cut-off of less than 20 ppb as normal and more than 35 ppb as re-
flective of the presence of inflammation in children (Dweik 2011).
However, it remains unknown how other significant influences of
FeNO should be considered. These influences include ethnicity
(ATS 2005) and atopy (Petsky 2015). Further, the FeNO cut-off
values used to adjust the medications varied among the studies
although it could be argued that the cut-off used should be indi-
vidualised with each child having their own baseline FeNO value.
None of the studies used this approach. Thus, it remains unknown
how best to use FeNO values.
Also, as FeNO levels reflect airway eosinophilia in steroid-naive
people, the results of the review are unlikely to apply to those
children with non-eosinophilic asthma.
In our review, there was a discordance between the beneficial effect
of using FeNO to guide asthma therapy for exacerbations com-
pared to other clinically important outcomes such as QoL, asthma
control and lung function. One possible reason relates to a type-
1 error (insufficient sample size). However, 724 participants used
the ACQ and 380 participants used the PACQLQ. Thus, it is
unlikely that there was a type-1 error present.
Lastly, none of the studies included in this review undertook a cost
analyses and its absence limits the applicability in ’real-life’ clinical
practice.
Quality of the evidence
The ’Summary of findings’ table summarises the evidence for
the three main outcomes relating to exacerbations and ICS dose.
Overall the quality of evidence was very low to moderate using
the GRADE system. As two studies were not blinded (de Jongste
2008; Verini 2010) and another (Voorend-van Bergen 2015) was
single blinded this reduced our confidence in these studies as they
introduced bias. Removing these studies for the sensitivity anal-
ysis, still showed a reduction in the number of exacerbations in
the FeNO group. However, we downgraded the evidence using
GRADE to moderate as displayed in Summary of findings for the
main comparison.
We downgraded the outcome of exacerbation rate to very low due
to the statistical heterogeneity (I2 = 67%, P = 0.03), imprecision
and risk of bias. The fact that a random-effects model showed
no difference between the groups, whereas a fixed-effect model
did show a difference, demonstrates the imprecision and potential
skew of the data. The study that likely contributed to the statistical
heterogeneity was that of Pike 2013 who stated that their data for
exacerbation rates was skewed when they provided further data to
us. Consequently, they reported their published data as medians
and interquartile ranges.
Potential biases in the review process
We are unaware of any biases in the review process. We used a
comprehensive search strategy and adhered to the protocol. Two
review authors (HP, KK) independently assessed the risk of bias.
We contacted the corresponding authors of all the studies for raw
data to include in the meta-analysis. One review author and the
review editor (Christopher Cates) independently checked data ex-
traction, risk of bias assessment and downgrading decisions for the
’Summary of findings’ tables to minimise the risk of bias in the
review process.
As twoof the review authors (HP,AC) conducted one of the studies
included in this review (Petsky 2015), a separate review author
(KK) made final decisions on this paper’s risk of bias.
Agreements and disagreements with other
studies or reviews
This review updated a previous Cochrane Review (Petsky 2009),
which included studies involving children and adults. The deci-
sion was to separate the review based on population ages and the
increased clinical trials on the subject. The original review included
two adult studies and four paediatric studies involving 1010 par-
ticipants (Petsky 2009). This paediatric review includes nine stud-
ies with 1329 children completing. A separate systematic review
on adults includes seven studies with 1546 participants complet-
ing (Petsky 2016). The review in adults found similar results to
this paediatric review.
Results from the original review (Petsky 2009) were different to
those of this current review. The old review found no significant
difference between the groups for the primary outcome of exacer-
bations. The four paediatric papers included in the original review
reported that the FeNO group experienced fewer exacerbations in
comparison to the control group, but the difference was not sig-
nificant (P = 0.06) when combining three studies in a meta-anal-
ysis (OR 0.75, 95% CI 0.55 to 1.01) (Pijnenburg 2005; Fritsch
2006; Szefler 2008; de Jongste 2008). However, combining the
data from eight studies in this review showed that the number of
participants experiencing an exacerbation was significantly lower
(P = 0.0002) in the FeNO group compared to the control group
(OR 0.62, 95% CI 0.49 to 0.80) (Pijnenburg 2005; Szefler 2008;
de Jongste 2008; Verini 2010; Pike 2013; Peirsman 2014; Petsky
2015; Voorend-van Bergen 2015). There was no heterogeneity
between the studies (I2 = 21%).
Lu 2015 completed a meta-analysis comparing the use of FeNO
versus guideline-based management for children with asthma.
They included six studies with 506 participants. Their results were
similar to this Cochrane Review. Lu and coworkers described that
significantly fewer participants in the FeNO group had exacerba-
tions compared to the control group (more than one exacerbation:
OR 0.69, 95%CI 0.53 to 0.90; P = 0.005). As with this Cochrane
Review, Lu 2015 described no difference between groups for the
outcomes of FeNO levels, FEV1 or ICS dose.
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Gomersal and colleagues conducted a systematic review but did
not undertake a meta-analysis comparing FeNO-guided manage-
ment with any other monitoring strategy for children with asthma
(Gomersal 2016). Their review included seven studies and the au-
thors stated that there was a “trend towards reduced exacerbation
and increased medications use” in the FeNO group. Furthermore,
they identified issues with heterogeneity between the algorithms
and included cohorts. They concluded that the benefits of utilising
FeNO monitoring in children with asthma remains ambiguous.
There are no guidelines currently that recommend the use of
FeNO routinely in monitoring asthma. However, guidelines from
theNational Institute forHealth andCare Excellence are currently
focusing on the impact and feasibility of implementing FeNO in
a diagnosis algorithm (NICE interim findings 2016).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review has demonstrated that tailoring asthma medications
based on exhaled nitric oxide (FeNO) levels significantly reduces
the number of children with one or more exacerbation (defined
as any exacerbation or rescue oral corticosteroid courses but not
hospitalisations) during the study period. However, use of the
FeNO strategy was not beneficial for exacerbation rates, or the
secondary outcomes of forced expiratory volume in one second
(FEV1), FeNO levels, inhaled corticosteroid doses or symptom
scores. Exacerbation rates were only significantly different between
groups when the less appropriate fixed-effect model was applied
to this outcome.
Thus, the use of FeNO to guide therapy decisions for medication
children with asthma cannot be universally advocated. The inter-
vention may be most useful in a subset of children with asthma.
Implications for research
Further double-blind, parallel group, randomised controlled trials
are required. Studies should be conducted in primary care and
consider various cut-offs for FeNO levels and other significant in-
fluences of FeNO levels such as atopy, sex and ethnicity. A ’one size
fits all’ approach in relation to FeNO levels may not be providing
a clear picture. The effect of tailoring asthma medications based
on different levels of asthma severity should also be considered.
Further cost analyses and adverse events of inhaled and oral corti-
costeroids would provide additional important information.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
de Jongste 2008
Methods Prospective, open-label, randomised, multicentre, parallel group study where ICS was
adjusted every 3 weeks based on FeNO and symptom scores, or symptom scores alone
4 randomised participants (2 in FeNO group, 2 in symptom group) were excluded from
final results due to severe non-compliance (2), inappropriate inclusion (no allergy 1) and
moving abroad (1)
Study duration 30 weeks.
Participants 151 children randomised.
FeNO group = 75: mean age 11.6 yrs (SD 2.6), 46 boys, 29 girls
Symptom group = 72: mean age 11.8 yrs (SD 4.3), 54 boys, 18 girls
Inclusion criteria: participants aged 6 to 18 yrs, stable mild-moderate asthma, diagnosed
according toGINA guidelines, treatment with 200µg to 1000µg of inhaled budesonide
or equivalent daily for 2 months prior to randomisation, and RAST class ≥ 2, or a
positive SPT to ≥ 1 airborne allergen
Exclusion criteria: active smoking, previous admission to an ICU for asthma and con-
comitant disease that might affect FeNO
Interventions All participants scored asthma symptoms in an electronic diary over 30 weeks
FeNO group: participants received a portable FeNO analyser. Data were transmitted
daily to the co-ordinating centres. Participants were telephoned every 3 weeks and their
steroid dose was adapted according to FeNO and symptoms
Control group: participants were treated according to symptoms
Children were seen at 3, 12, 21 and 30 weeks for examination, assessment of FeNO,
spirometry before and after salbutamol, and recording of adverse events
Outcomes Primary outcome: proportion of symptom-free days over the last 12 study weeks
Secondary outcomes: cumulative symptom scores, ICS dose as budesonide equivalent,
FEV1 and reversibility, FeNO0.05, prednisone courses, emergency visits, hospitalisations
for asthma and PACQLQ scores
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information in the published
article.
Allocation concealment (selection bias) Unclear risk Insufficient information of randomisation
in published article
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de Jongste 2008 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label study - no blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label study - no blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Intention to treat analysis was performed
for all subjects who were enrolled” (stated
in published article)
Selective reporting (reporting bias) Unclear risk Outcomes were reported incompletely and
were unable to be included in the meta-
analysis
Other bias High risk The calibration of the NIOX Minos after
the study showed drift outside the manu-
facturer’s specifications in 11 of 77 instru-
ments. The article has also reported that “a
number” of the Niox Mino’s had to be re-
placed as a risk of malfunctioning was de-
tected
The study was supported by the com-
pany (Aerocrine AB, Sweden) who manu-
factured the FeNO analyser
Fritsch 2006
Methods A prospective, randomised, single-blind parallel trial examining the inclusion of repeated
FeNOmeasurements into asthma monitoring over 6 months. In the FeNO group, treat-
ment was based on symptoms, beta-agonists use, lung function and FeNO. Treatment
of the control group was based on symptoms, beta-agonists use and lung function only
5 participants dropped out, unsure of when these occurred.
Over the 6 months, there were 5 visits at 6-week intervals.
Participants 52 participants entered the study.
FeNO group: n = 22; mean age 11.3 yrs (SD 3.4), 14 boys, 8 girls
Control group: n = 25; mean age 12.1 yrs (SD 2.8), 14 boys, 11 girls
Attended paediatric pulmonology outpatient clinic fromUniversity Children’s Hospital,
Vienna
Inclusion: aged 6 to 18 yrs with asthma diagnosis as based onAmericanThoracic Society’s
criteria. Positive SPT or RAST > 1
Exclusion: children who had received oral or IV steroid treatment 4 weeks prior to their
first visit
Interventions Participants were run-in for 4 weeks. Randomised at visit 1 then outpatient visits at 6,
12, 18 and 24 weeks
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Fritsch 2006 (Continued)
FeNO group: treatment based on symptoms, beta-agonist use, lung function and FeNO
Control group: treatment based on symptoms, beta-agonist use and lung function
Outcomes Primary outcome: FEV1
Secondary outcomes: number of exacerbations, MEF 50%predicted, better symptom
control, lower SABA and ICS dose
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information of randomisation
in published article. No details on ran-
domisation methods
Allocation concealment (selection bias) Unclear risk Insufficient information of randomisation
in published article
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided, unsure
of who was aware of group allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Insufficient information provided on why
dropouts occurred.
Selective reporting (reporting bias) High risk Primary outcome not reported completely
to allow data to be entered into the meta-
analysis
Other bias High risk FeNO measurements could not be per-
formed in 23 observations due to technical
problems, whether this provided a bias was
unclear. Aerocrine (analyser manufacturer)
assisted with data analysis
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Peirsman 2014
Methods Randomised, single-blind, parallel study comparing asthma treatment adjusted based on
GINA guidelines (clinical group) vs treatment guided by FeNO (FeNO group)
Participants had 5 visits (baseline, and months 3, 6, 9 and 12)
6 children did not complete the study (4 in clinical group, 2 in FeNO group)
Participants 99 children randomised.
FeNO group: n = 49; mean age 10.6 yrs (SD 2.2), 33 boys, 16 girls
Clinical group: n = 50; mean age 10.7 yrs (SD 2.1), 33 boys, 17 girls
Children recruited from 7 Belgian hospitals.
Inclusion criteria: children with mild-to-severe asthma according to GINA guidelines for
> 6 months and allergic sensitisation (i.e. positive SPT or specific IgE antibodies against
inhalant allergens)
Exclusion criteria: significant comorbidity, acute asthma exacerbation or taken experi-
mental medication 4 weeks prior to the screening visit, hospitalisation or systemic cor-
ticosteroids 12 weeks prior to screening visit (or both), or OCS dependency
Interventions FeNO group: treatment aimed to keep FeNO below 20 ppb.
Clinical group: treatment based on GINA guidelines (i.e. reporting of symptoms, need
for rescue treatment in preceding 2 weeks and FEV1).
Outcomes Primary outcome: symptom-free days using first 4 questions from childhood ACT
Secondary outcomes: occurrence of exacerbations, unscheduled asthma-related contacts,
hospital or emergency department admissions, non-attendance to school and career’s
work absence
Notes Study funded partially by Merck & Co and FeNO analysers supplied by Aerocrine but
neither were involved in any part of the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as an RCT but no methods re-
ported.
Allocation concealment (selection bias) Low risk Stated that an independent nurse blinded
to all participant characteristics allocated
the children to the 2 groups
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were blinded and physicians
blinded to FeNO in clinical group only
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Physician blinded to FeNO in clinical
group. Insufficient information in pub-
lished article for FeNO group and whether
physician was blinded to clinical symptoms
in the FeNO group
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Peirsman 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout rate was low and balanced.
Selective reporting (reporting bias) Low risk All outcome data were presented in pub-
lished article.
Other bias Unclear risk No information provided on the success
in obtaining FeNO measurements at each
visit
Petsky 2015
Methods Randomised, double-blind, parallel study evaluated whether a treatment strategy based
on FeNO levels, adjusted for atopy (FeNO group), in comparison to treatment strategy
based on clinical symptoms (control group) could reduce asthma exacerbations
Participants had 10 visits over 12 months (run-in, initial, months 1, 2, 3, 4, 6, 8, 10 and
12)
8 children did not complete the study (4 in FeNO group and 4 in control group)
Participants FeNO group: n = 31, median age 10.17 yrs (IQR 6.56 to 12.69), 18 boys, 13 girls
Symptom group: n = 32, median age 10.08 yrs (IQR 6.25 to 12.44), 13 boys, 19 girls
Inclusion criteria: children aged > 4 yrs with persistent asthma, prescribed anti-inflam-
matory asthma treatment and receiving their care primarily through 2 hospitals (Bris-
bane and Hong Kong)
Exclusion criteria: underlying cardio-respiratory illnesses such as bronchiectasis or tra-
cheomalacia, inability to take ICS or LABA, or previous poor adherence to medications
as documented in medical charts
Interventions FeNO group: treatment adjusted on FeNO levels and atopic status
Symptom group: treatment adjusted as recorded on asthma symptom diary card
Outcomes Primary outcome: severe exacerbations defined as respiratory events requiring course of
OCS with or without hospitalisation
Secondary outcomes: FEV1 %predicted, asthma QoL, symptom scores and dose of ICS
at end of study (budesonide equivalent)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation done by an independent
individual off site through computer gen-
eration
Allocation concealment (selection bias) Low risk Allocation fully concealed using opaque
covers.
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Petsky 2015 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind - decisions to adjust therapy
was made by investigators who blinded to
participant’s group, and parents and chil-
dren blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Treatment determined by primary physi-
cian. Two review authors listed as study au-
thors (HP and CA). They could not be
blinded but they did not make decisions in
this study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout rates low. Intention to treat anal-
yses were used.
Selective reporting (reporting bias) High risk Secondary outcomes not reported in suffi-
cient details in the published paper to in-
clude in a meta-analysis
Other bias Low risk None noted.
Pijnenburg 2005
Methods Randomised, double-blind study evaluating whether titrating steroids on FeNO im-
proved asthma management in children. Stratified by baseline FeNO (> 30 or < 30 ppb)
and dose of ICS (> 400 µg/day or < 400 µg/day of budesonide or equivalent)
Neither participants nor physicians were aware of which group they were randomised to
7 dropouts: 3 during run-in, 3 from FeNO group (1 admitted to ICU) and 1 from
symptom group
Study duration 12 months, with 5 visits at 3-monthly intervals
Participants 89 children randomised from 108 invited from outpatient clinic
FeNO group n = 39: mean age 11.9 yrs (SD 2.9), 25 boys, 14 girls
Symptom group n = 46: mean age 12.6 yrs (SD 2.8), 30 boys, 16 girls
Inclusion: use of ICS at constant dose for at least 3 months preceding study. Atopy
defined as RAST class ≥ 2 for at least 1 airborne allergen
Interventions Children were run-in for 2 weeks, then 3-monthly visits.
FeNO group: FeNO-guided ICS dosing according to predetermined algorithm
Symptom group: symptom scores influenced ICS dosing.
Outcomes Primary outcome: cumulative steroid dose (sum of mean daily steroid doses of visits 1
to 5)
Secondary outcomes: mean daily symptom score, mean daily number of bronchodilator
doses taken, % of symptom-free days during the last 4 weeks of the study, number of
oral prednisone courses during the study, and provocative dose of methacholine causing
a 20% fall in FEV1, FVC and MEF25 during final visit.
Notes
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Pijnenburg 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information of randomisation
in published article
Allocation concealment (selection bias) Unclear risk Insufficient information of randomisation
in published article
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind - parents and physician were
blinded to allocated group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators provided the physician with
an ICS dose recommendation according to
predetermined algorithm
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout rates low but unbalanced between
groups.
Selective reporting (reporting bias) Unclear risk All outcomes reported, however the symp-
tom scores could not be included in meta-
analyses
Other bias Unclear risk No information provided on the success
in obtaining FeNO measurements at each
visit
Pike 2013
Methods Randomised, double-blind, parallel-group trial. Participants were assigned to either
FeNO-based or standard management strategy arms, and asthma treatment adjusted
according to a predetermined algorithm
Participants and physicians not aware of their allocation.
Study duration 12 months with study visits every 2 months.
13 children did not complete the study; 10 in FeNOgroup (8withdrew, 1 non-adherence
to protocol, 1 life-threatening exacerbation) and 3 withdrew in Standard management
group
Participants 90 children randomised from 96 screened.
FeNO group n = 44: mean age 10.51 yrs (SD 2.62), 21 boys, 23 girls
Standard management group n = 46: mean age 11.42 yrs (SD 2.69), 30 boys, 16 girls
Inclusion criteria: aged 6 to 17 yrs, clinical diagnosis of asthma and treatment with
beclomethasone dipropionate/budesonide ≥ 400 µg/day or fluticasone ≥ 200 µg/day.
Asthma diagnosed upon a history of symptoms, ≥ 15% increase in FEV1 with bron-
chodilator or diurnal PEF variability ≥ 15%.
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Pike 2013 (Continued)
Interventions Participants needed to be stabilised prior to randomisation, then 2 monthly visits
FeNO group: FeNO measurements and symptom control.
Standard management group: symptom control as per blinded clinician (reliever use,
FEV1).
Outcomes Change in ICS dose, exacerbation frequency, FeNO measurements and lung function
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
according to site. Stratified by ICS dose
(400 µ/day to 800 µg/day or > 800 µg/
day of beclomethasone dipropionate equiv-
alent)
Allocation concealment (selection bias) Low risk Computer-generated block randomisation
according to site. Stratified by ICS dose
(400 µg/day to 800 µg/day or > 800 µg/
day beclomethasone dipropionate equiva-
lent)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind - parents and physician were
blinded to allocated group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Ablinded clinician categorised asthma con-
trol level and therapy decisions were made
by an independent clinician following a
predetermined algorithm
Incomplete outcome data (attrition bias)
All outcomes
High risk 10 children fromFeNOgroup vs 3 children
from standard management group did not
complete the study
Selective reporting (reporting bias) Unclear risk Baseline data not shown and reported as
such in publication.
Other bias High risk Singlemeasurement of FeNO taken at each
visit, not as per AmericanThoracic Society/
European Respiratory Society guidelines
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Szefler 2008
Methods Randomised, double-blind, parallel-group trial. Participants had their asthma manage-
ment based on standard treatment as per NAEPP guidelines of or standard treatment
modified based on measurements of FeNO
Participants and physicians were unaware of the treatment assignment
Study duration 46 weeks, with visits every 6 to 8 weeks.
12 randomised participants were lost to follow-up before the first outcome data were
collected. During the 46-week follow-up, 17 participants in FeNO group dropped out
and 23 in the control group
Participants 546 participants randomised from 780 children screened.
FeNO group n = 276: mean age 14.4 yrs, 146 boys, 130 girls.
Control group n = 270: mean age 14.4 yrs, 142 boys, 128 girls
Inclusion criteria: aged 12 to 20 yrs, diagnosedwith asthma by their physician, symptoms
of persistent asthma or evidence of uncontrolled disease as defined byNAEPP guidelines,
and residents of urban census tracts in which at least 20% of households had incomes
below the federal poverty threshold
Interventions Run-in period of 3 weeks then scheduled visits every 6 to 8 weeks for 46 weeks
At each visit FeNOwas measured, days of asthma symptoms assessed, use of rescue drugs,
pulmonary function, use of health care, adherence to treatment regimen and missed days
of school because of asthma
FeNO group: standard treatment modified based on measurements of FeNO
Control group: standard treatment based on the guidelines of NAEPP
Outcomes Primary outcome: number of days with asthma symptoms.
Secondary outcomes: admission to hospital, unscheduled visits to emergency depart-
ments or clinics, prednisone courses for asthma, asthma exacerbations, days of wheeze,
days of interference with activities, nights of sleep deprivation, days of school or work
missed, and days of interruption of guardian’s activities
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised block randomisation with a
block size of 10. Randomisation sequence
was generated from a random number ta-
ble and was stratified by site using statisti-
cal software
Allocation concealment (selection bias) Low risk Randomisation sequence generated from a
random number table and stratified by site
using statistical software
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind - participants and physician.
A computer program generated the treat-
ment option for each participant according
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Szefler 2008 (Continued)
to their allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All individual participant datawere entered
into a computer program which selected
the treatment option for that participant
based on their allocation and the treatment
step. A co-ordinator aware of the treatment
allocation gave the physician the appropri-
ate treatment regimen, as generated by the
computer algorithm
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout was low and balanced between
groups. Analysis done on intention to treat
Selective reporting (reporting bias) High risk No explanation given formissing data. Sec-
ondary outcome, days of interruption to
guardian’s activities, not reported. Adher-
ence reported but stated only run-in pe-
riod adherencemeasuredwith built-in dose
counter
Other bias Unclear risk No information published on the success of
obtaining FeNOmeasurements. On enrol-
ment, doses of ICS were increased by mean
of 219 µg (95% CI 199 to 238) which is
a large increase and could influence the re-
porting of participants
Verini 2010
Methods Randomised, open-label, parallel-group trial. Participants had their asthma treatment
adjusted based on GINA guidelines (GINA group) or GINA guidelines and FeNO
measurements (FeNO group)
Study duration 12 months with 3 visits (baseline, months 6 and 12)
All children completed the study.
Participants FeNO group n = 32: mean age 10.7 yrs (SD 2.4), 18 boys, 14 girls
GINA group n = 32: mean age 11.3 yrs (SD 2.1), 18 boys, 14 girls
Inclusion criteria: all children had been admitted for allergic asthma and the diagnosis
physician based according to ATS/ERS criteria
Interventions Children reviewed 3 times over 12 months’ study duration.
At baseline and month 12 visits all children had clinical evaluation, allergy evaluation
(SPT and IgE), lung function tests, FeNO measurement, diary card and asthma score
therapy prior to randomisation
GINA group: at month 6 had diary card and clinical evaluation
FeNO group: at month 6 had diary card, clinical evaluation, lung function test, FeNO
measurement and asthma score therapy
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Verini 2010 (Continued)
Outcomes No clear definition given of outcomes, however asthma severity score, asthma exacerba-
tion frequency and asthma therapy score were the main items reported in results section
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information given regarding randomi-
sation.
Allocation concealment (selection bias) Unclear risk No information given regarding randomi-
sation.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label - both physician andparticipant
knew allocation group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding, therefore high risk of detec-
tion bias.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of dropouts, however stated
whole study population was assessed at
baseline, 6 months and at end of study
Selective reporting (reporting bias) High risk Lung function results not reported for any
time points despite being measured in both
groups at all visits. Additionally, baseline
and final FeNOmeasurements were not in-
cluded for the GINA group
Other bias Unclear risk No funding information provided. No in-
formation given on the success of obtain-
ing FeNO levels at each visit
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Voorend-van Bergen 2015
Methods Multicentre, prospective, single-blind, parallel-group, 3-armed RCT. 2 monitoring
strategies compared with standard care
Web-based strategy used ACT to adjust treatment via a website at 1 monthly intervals
FeNO-based strategy used FeNO and ACT.
Standard care strategy used ACT at 4 monthly visits.
The physicians were blinded to allocation, FeNO and ACT. Treatment plans were given
to the physicians through local investigators based on the study algorithms
Study duration 12 months with visits at 4 monthly intervals. 1 randomised participant
from web-based group did not complete the 12-month follow-up
Participants 272 children randomised from 481 screened.
Web-based group n = 91: mean age 10.6 yrs (SD 2.8), 60 boys, 31 girls
FeNO group n = 92: mean age 10.3 yrs (SD 2.9), 62 boys, 30 girls
Standard care group n = 89: mean age 10.2 yrs (SD 3.2), 61 boys, 28 girls
Inclusion criteria: aged 4 to 18 yrs, atopic asthma based on clinical symptoms, previous
bronchodilator response > 9% increase in FEV1, previous airway hyper-responsiveness
to methacholine.
Interventions Run-in period of 4 weeks, then 4 monthly visits.
At each visit FeNO, ACT and diary was assessed. Additionally, at visit 1 and visit 4 FEV1
and PD20 were measured.
Web group: treatment modified by ACT and adherence.
FeNO group: treatment modified by ACT and FeNO.
Standard care group: treatment modified by ACT.
Outcomes Primary outcome: changes from baseline of proportion of symptom-free days
Secondary outcomes: changes from baseline of ACT, daily symptom score, daily bron-
chodilator use, daily ICS dose, asthma-relatedQoL, dose of methacholine causing a 20%
fall in FEV1 (PD20), FVC, FEV1 and MEF25 and exacerbations during the study.
Notes We used the standard care strategy as the control group and did not consider the web-
based strategy in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation program on study website,
equal randomisation (1:1:1)
Allocation concealment (selection bias) Unclear risk Randomisation done through computer
program on study website but no explana-
tion if concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Single blinded - participants not blinded to
allocation. Physician blinded to allocation
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Voorend-van Bergen 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators not blinded provided the
physicians with treatment advice based on
the study algorithm
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcomes reported when including the
supplementary material
Selective reporting (reporting bias) Low risk All outcomes reported when including the
supplementary material
Other bias Unclear risk FeNOwas measured using 2 different anal-
ysers, 1 chemiluminescence and 1 portable.
Not explained if individual participants
used the same type at each visit
ACT: Asthma Control Test; CI: confidence interval; FeNO: fractional exhaled nitric oxide; FeNO0.05: fractional exhaled nitric oxide
at an expiratory flow rate of 50 mL/second;
FEV1: forced expiratory volume in one second; FVC: forced vital capacity; GINA: Global Initiative for Asthma; ICS: inhaled corti-
costeroid; ICU: intensive care unit; Ig: immunoglobulin; IQR: interquartile range; IV: intravenous; LABA: long-acting beta2 agonist;
MEF25: maximal expiratory flow at 25% of vital flow capacity; MEF 50%predicted: maximum expiratory flow at 50% of predicted; n:
number of participants; NAEPP: National Asthma Education and Prevention Program; OCS: oral corticosteroid; PD20: administered
dose of a substance in the inhaled aerosol which causes the FEV1 to fall by 20%; PEF: peak expiratory flow; PACQLQ: Paediatric
Asthma Caregiver’s Quality of Life Questionnaire; ppb: parts per billion; QoL: quality of life; RAST: radioallergosorbent test; RCT:
randomised controlled trial; SABA: short-acting beta2 agonist; SD: standard deviation; SPT: skin prick test; yrs: years.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anderson 2012 Treatment not adjusted according to FeNO. Randomised, cross-over trial evaluating the dose response of
inhaled corticosteroids in adults with asthma and elevated FeNO
Calhoun 2012 Did not include children/adolescents but based in adult population. Included in adult Cochrane systematic
review by same authors (Petsky 2016).
Gelb 2006 Not a RCT or treatment based on FeNO. Prospective study to assess FeNO and spirometry to predict asthma
exacerbations
Griese 2000 Not a RCT or treatment based on FeNO. Prospective study to assess FeNO in comparison to symptoms
adjusted using clinical symptoms
Hashimoto 2011 Study did not include children/adolescents but based in adult population. Included in adult Cochrane sys-
tematic review by same authors (Petsky 2016).
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(Continued)
Honkoop 2015 Study did not include children/adolescents but based in adult population. Included in adult Cochrane sys-
tematic review by same authors (Petsky 2016).
Jatakanon 1999 Treatment not based on FeNO. Randomised into 2 double-blind, placebo-controlled studies (1 parallel study
involving 3 groups receiving budesonide 110 µg/day, budesonide 400 µg/day or placebo. Second was a cross-
over randomised study to receive budesonide 1600 µg or placebo)
Jones 2001 Not a RCT. Observational study to determine if FeNO is useful in diagnosing and predicting loss of asthma
control. Participants had ICS withdrawn until loss of control or for a maximum of 6 weeks
Jones 2002 Treatment not based on FeNO. Double-blind, parallel-group, placebo-controlled trial of budesonide 50 µg/
day, 100 µg/day, 200 µg/day or 500 µg/day
Kharitonov 1996 Not a RCT. Observational study of the effect of increasing and then reducing the dose of ICS on FeNO, lung
function and symptoms in people with asthma
Kharitonov 2002 Treatment not adjusted according to FeNO.Double-blind, placebo-controlled, parallel-group study of budes-
onide 100 µg or 400 µg or placebo daily dose in people with mild asthma
Lim 1998 Excluded as treatment not adjusted according to FeNO. Randomised, longitudinal study monitoring the
effect of increasing anti-inflammatory medication or to continue unchanged using conventional measures of
lung function, symptom scores, medication usage and peak expiratory flow rate variability
Malerba 2008 Excluded as non-randomised. Prospective observational study including 14 participants with asthma who
had asthma treatment adjusted based on sputum eosinophil counts and FeNO
Powell 2011 Excluded as study did not include children/adolescents but based in adult population. Included in adult
Cochrane systematic review by same authors (Petsky 2016).
Shaw 2007 Excluded as study did not include children/adolescents but based in adult population. Included in adult
Cochrane systematic review by same authors (Petsky 2016).
Smith 2005 Excluded as study did not include children/adolescents but based in adult population. Included in adult
Cochrane systematic review by same authors (Petsky 2016).
Syk 2013 Excluded as study did not include children/adolescents but based in adult population. Included in adult
Cochrane systematic review by same authors (Petsky 2016).
Zacharasiewicz 2005 Not a RCT. Prospective and observation study in children using non-invasive measures (FeNO, induced
sputum and exhaled breath condensate) to monitor airway inflammation to result in optimal treatment
FeNO: fractional exhaled nitric oxide; ICS: inhaled corticosteroid; RCT: randomised controlled trial.
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Characteristics of ongoing studies [ordered by study ID]
Duong-Quy 2015
Trial name or title Exhaled NO (FeNO)Measurement used to Determine Asthma Control, Dose of Inhaled Corticosteroid and
Cost in a Developing Country
Methods People with uncontrolled asthma with FeNO > 25 ppb included. Classified into 3 groups according to
intervention used to determine therapy
Participants Unknown
Interventions Group 1: used GINA guidelines.
Group 2: used GINA + FeNO.
Group 3: used FeNO alone.
Outcomes ICS dose, exacerbations, cost.
Starting date Unknown.
Contact information Sy Duong-Quy email sduongquy.jfvp@gmail.com.
Notes Contacted Prof Duong-Quy January 2016, he stated that the article will be submitted in the ’near future’
FeNO: fractional exhaled nitric oxide; GINA: Global Initiative for Asthma; ICS: inhaled corticosteroid; ppb: parts per billion.
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D A T A A N D A N A L Y S E S
Comparison 1. Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants who had
≥ 1 exacerbations over study
period
8 1279 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.45, 0.75]
2 Number of asthma exacerbations
per 52 weeks (exacerbation
rates)
4 736 Mean Difference (IV, Random, 95% CI) -0.37 [-0.80, 0.06]
3 Number of participants with
severe exacerbations requiring
hospitalisation
6 1110 Odds Ratio (M-H, Fixed, 95% CI) 0.75 [0.41, 1.36]
4 Number of participants with
severe exacerbations requiring
rescue oral corticosteroids
7 1169 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.48, 0.83]
5 FEV1 %predicted at final visit 7 1181 Mean Difference (Fixed, 95% CI) 1.00 [-0.07, 2.07]
6 FeNO geometric mean level at
final visit
3 356 Geometric Mean (Fixed, 95% CI) 0.98 [0.87, 1.11]
7 Symptom score as per Asthma
Control Test
2 724 Mean Difference (IV, Fixed, 95% CI) 0.14 [-0.18, 0.47]
8 Symptom score as per quality of
life
3 380 Mean Difference (Fixed, 95% CI) 0.09 [-0.08, 0.27]
9 Inhaled corticosteroid dose
at final visit (budesonide
equivalent)
3 317 Mean Difference (IV, Fixed, 95% CI) 63.95 [-51.89, 179.
79]
10 Number of participants who
had ≥ 1 exacerbations over
study period (subgrouped by
method used in control group).
8 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Guideline driven 4 799 Odds Ratio (M-H, Fixed, 95% CI) 0.67 [0.51, 0.90]
10.2 Other control 4 480 Odds Ratio (M-H, Fixed, 95% CI) 0.55 [0.34, 0.90]
11 Number of exacerbations per
52 weeks (exacerbation rates)
(subgrouped by method used
in control group)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 Guideline driven 3 673 Mean Difference (IV, Fixed, 95% CI) -0.27 [-0.49, -0.06]
11.2 Other control 1 63 Mean Difference (IV, Fixed, 95% CI) -0.39 [-0.84, 0.06]
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Analysis 1.1. Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus
clinical symptoms, Outcome 1 Number of participants who had ≥ 1 exacerbations over study period.
Review: Exhaled nitric oxide levels to guide treatment for children with asthma
Comparison: 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms
Outcome: 1 Number of participants who had≥ 1 exacerbations over study period
Study or subgroup FeNO strategy Control strategy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
de Jongste 2008 9/75 12/72 6.9 % 0.68 [ 0.27, 1.73 ]
Peirsman 2014 11/49 22/50 10.7 % 0.37 [ 0.15, 0.88 ]
Petsky 2015 6/31 15/32 7.6 % 0.27 [ 0.09, 0.84 ]
Pijnenburg 2005 7/42 10/47 5.0 % 0.74 [ 0.25, 2.16 ]
Pike 2013 37/44 38/46 3.8 % 1.11 [ 0.37, 3.38 ]
Szefler 2008 91/276 115/270 49.6 % 0.66 [ 0.47, 0.94 ]
Verini 2010 16/32 26/32 8.3 % 0.23 [ 0.07, 0.71 ]
Voorend-van Bergen 2015 9/92 14/89 8.2 % 0.58 [ 0.24, 1.42 ]
Total (95% CI) 641 638 100.0 % 0.58 [ 0.45, 0.75 ]
Total events: 186 (FeNO strategy), 252 (Control strategy)
Heterogeneity: Chi2 = 7.54, df = 7 (P = 0.38); I2 =7%
Test for overall effect: Z = 4.19 (P = 0.000028)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus
clinical symptoms, Outcome 2 Number of asthma exacerbations per 52 weeks (exacerbation rates).
Review: Exhaled nitric oxide levels to guide treatment for children with asthma
Comparison: 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms
Outcome: 2 Number of asthma exacerbations per 52 weeks (exacerbation rates)
Study or subgroup FeNO strategy Control strategy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Petsky 2015 31 0.39 (0.71) 32 0.78 (1.07) 28.8 % -0.39 [ -0.84, 0.06 ]
Pike 2013 28 3.71 (2.54) 35 3.2 (2.11) 10.3 % 0.51 [ -0.66, 1.68 ]
Szefler 2008 276 0.66 (1.41) 270 0.84 (1.4) 37.0 % -0.18 [ -0.42, 0.06 ]
Verini 2010 32 0.83 (0.98) 32 1.85 (1.34) 24.0 % -1.02 [ -1.60, -0.44 ]
Total (95% CI) 367 369 100.0 % -0.37 [ -0.80, 0.06 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 9.00, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 1.68 (P = 0.093)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus
clinical symptoms, Outcome 3 Number of participants with severe exacerbations requiring hospitalisation.
Review: Exhaled nitric oxide levels to guide treatment for children with asthma
Comparison: 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms
Outcome: 3 Number of participants with severe exacerbations requiring hospitalisation
Study or subgroup FeNO strategy Control strategy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
de Jongste 2008 4/75 10/72 38.6 % 0.35 [ 0.10, 1.17 ]
Peirsman 2014 1/43 1/43 3.9 % 1.00 [ 0.06, 16.52 ]
Petsky 2015 0/31 0/32 Not estimable
Pike 2013 5/44 3/46 10.4 % 1.84 [ 0.41, 8.20 ]
Szefler 2008 9/276 11/270 43.0 % 0.79 [ 0.32, 1.95 ]
Voorend-van Bergen 2015 1/91 1/87 4.0 % 0.96 [ 0.06, 15.52 ]
Total (95% CI) 560 550 100.0 % 0.75 [ 0.41, 1.36 ]
Total events: 20 (FeNO strategy), 26 (Control strategy)
Heterogeneity: Chi2 = 3.00, df = 4 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus
clinical symptoms, Outcome 4 Number of participants with severe exacerbations requiring rescue oral
corticosteroids.
Review: Exhaled nitric oxide levels to guide treatment for children with asthma
Comparison: 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms
Outcome: 4 Number of participants with severe exacerbations requiring rescue oral corticosteroids
Study or subgroup FeNO strategy Control strategy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
de Jongste 2008 9/75 12/72 8.6 % 0.68 [ 0.27, 1.73 ]
Fritsch 2006 2/22 2/25 1.4 % 1.15 [ 0.15, 8.93 ]
Peirsman 2014 2/49 3/50 2.3 % 0.67 [ 0.11, 4.17 ]
Petsky 2015 6/31 15/32 9.5 % 0.27 [ 0.09, 0.84 ]
Pijnenburg 2005 7/42 10/47 6.2 % 0.74 [ 0.25, 2.16 ]
Szefler 2008 91/276 115/270 61.9 % 0.66 [ 0.47, 0.94 ]
Voorend-van Bergen 2015 9/91 14/87 10.2 % 0.57 [ 0.23, 1.40 ]
Total (95% CI) 586 583 100.0 % 0.63 [ 0.48, 0.83 ]
Total events: 126 (FeNO strategy), 171 (Control strategy)
Heterogeneity: Chi2 = 2.70, df = 6 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.26 (P = 0.0011)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus
clinical symptoms, Outcome 5 FEV1 %predicted at final visit.
Review: Exhaled nitric oxide levels to guide treatment for children with asthma
Comparison: 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms
Outcome: 5 FEV1 %predicted at final visit
Study or subgroup FeNO strategy Control strategy Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
de Jongste 2008 75 72 1 (2.3099) 5.6 % 1.00 [ -3.53, 5.53 ]
Peirsman 2014 47 46 2.7 (2.8984) 3.6 % 2.70 [ -2.98, 8.38 ]
Petsky 2015 27 28 19.321 (5.7874) 0.9 % 19.32 [ 7.98, 30.66 ]
Pijnenburg 2005 39 46 2.3 (2.0919) 6.8 % 2.30 [ -1.80, 6.40 ]
Pike 2013 34 43 -3 (2.9595) 3.4 % -3.00 [ -8.80, 2.80 ]
Szefler 2008 276 270 0.8 (0.648) 71.2 % 0.80 [ -0.47, 2.07 ]
Voorend-van Bergen 2015 91 87 0.6 (1.8816) 8.4 % 0.60 [ -3.09, 4.29 ]
Total (95% CI) 589 592 100.0 % 1.00 [ -0.07, 2.07 ]
Heterogeneity: Chi2 = 12.72, df = 6 (P = 0.05); I2 =53%
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus
clinical symptoms, Outcome 6 FeNO geometric mean level at final visit.
Review: Exhaled nitric oxide levels to guide treatment for children with asthma
Comparison: 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms
Outcome: 6 FeNO geometric mean level at final visit
Study or subgroup FeNO strategy Control strategy
log [Geo-
metric
Mean]
Geometric
Mean Weight
Geometric
Mean
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
de Jongste 2008 50 39 -0.01 (0.1403) 18.9 % 0.99 [ 0.75, 1.30 ]
Pijnenburg 2005 42 47 -0.2776 (0.1231) 24.5 % 0.76 [ 0.60, 0.96 ]
Voorend-van Bergen 2015 91 87 0.0953 (0.081) 56.6 % 1.10 [ 0.94, 1.29 ]
Total (95% CI) 183 173 100.0 % 0.98 [ 0.87, 1.11 ]
Heterogeneity: Chi2 = 6.41, df = 2 (P = 0.04); I2 =69%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus
clinical symptoms, Outcome 7 Symptom score as per Asthma Control Test.
Review: Exhaled nitric oxide levels to guide treatment for children with asthma
Comparison: 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms
Outcome: 7 Symptom score as per Asthma Control Test
Study or subgroup FeNO strategy Control strategy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Szefler 2008 276 21.89 (2.0266) 270 21.83 (2.0266) 91.1 % 0.06 [ -0.28, 0.40 ]
Voorend-van Bergen 2015 91 22.4 (3.5) 87 21.4 (3.9) 8.9 % 1.00 [ -0.09, 2.09 ]
Total (95% CI) 367 357 100.0 % 0.14 [ -0.18, 0.47 ]
Heterogeneity: Chi2 = 2.60, df = 1 (P = 0.11); I2 =62%
Test for overall effect: Z = 0.87 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus
clinical symptoms, Outcome 8 Symptom score as per quality of life.
Review: Exhaled nitric oxide levels to guide treatment for children with asthma
Comparison: 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms
Outcome: 8 Symptom score as per quality of life
Study or subgroup FeNO strategy Control strategy Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
de Jongste 2008 75 72 0 (0.1239) 50.4 % 0.0 [ -0.24, 0.24 ]
Petsky 2015 27 28 0.33 (0.3683) 5.7 % 0.33 [ -0.39, 1.05 ]
Voorend-van Bergen 2015 91 87 0.17 (0.1327) 43.9 % 0.17 [ -0.09, 0.43 ]
Total (95% CI) 193 187 100.0 % 0.09 [ -0.08, 0.27 ]
Heterogeneity: Chi2 = 1.31, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus
clinical symptoms, Outcome 9 Inhaled corticosteroid dose at final visit (budesonide equivalent).
Review: Exhaled nitric oxide levels to guide treatment for children with asthma
Comparison: 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms
Outcome: 9 Inhaled corticosteroid dose at final visit (budesonide equivalent)
Study or subgroup FeNO strategy Control strategy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Petsky 2015 31 487 (497) 32 266 (312) 31.7 % 221.00 [ 15.34, 426.66 ]
Pike 2013 33 755 (518) 43 784 (597) 21.3 % -29.00 [ -280.15, 222.15 ]
Voorend-van Bergen 2015 91 400 (600) 87 400 (550) 47.0 % 0.0 [ -168.98, 168.98 ]
Total (95% CI) 155 162 100.0 % 63.95 [ -51.89, 179.79 ]
Heterogeneity: Chi2 = 3.32, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus
clinical symptoms, Outcome 10 Number of participants who had ≥ 1 exacerbations over study period
(subgrouped by method used in control group)..
Review: Exhaled nitric oxide levels to guide treatment for children with asthma
Comparison: 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms
Outcome: 10 Number of participants who had≥ 1 exacerbations over study period (subgrouped by method used in control group).
Study or subgroup FeNO strategy Control strategy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Guideline driven
Peirsman 2014 11/49 22/50 15.1 % 0.37 [ 0.15, 0.88 ]
Pike 2013 37/44 28/46 3.9 % 3.40 [ 1.25, 9.25 ]
Szefler 2008 91/276 115/270 69.5 % 0.66 [ 0.47, 0.94 ]
Verini 2010 16/32 26/32 11.6 % 0.23 [ 0.07, 0.71 ]
Subtotal (95% CI) 401 398 100.0 % 0.67 [ 0.51, 0.90 ]
Total events: 155 (FeNO strategy), 191 (Control strategy)
Heterogeneity: Chi2 = 15.35, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 2.67 (P = 0.0076)
2 Other control
de Jongste 2008 9/75 12/72 24.8 % 0.68 [ 0.27, 1.73 ]
Petsky 2015 6/31 15/32 27.4 % 0.27 [ 0.09, 0.84 ]
Pijnenburg 2005 7/42 10/47 18.1 % 0.74 [ 0.25, 2.16 ]
Voorend-van Bergen 2015 9/92 14/89 29.6 % 0.58 [ 0.24, 1.42 ]
Subtotal (95% CI) 240 240 100.0 % 0.55 [ 0.34, 0.90 ]
Total events: 31 (FeNO strategy), 51 (Control strategy)
Heterogeneity: Chi2 = 2.01, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.38 (P = 0.017)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 =0.0%
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Analysis 1.11. Comparison 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus
clinical symptoms, Outcome 11 Number of exacerbations per 52 weeks (exacerbation rates) (subgrouped by
method used in control group).
Review: Exhaled nitric oxide levels to guide treatment for children with asthma
Comparison: 1 Asthma treatment tailored on fractional exhaled nitric oxide (FeNO) versus clinical symptoms
Outcome: 11 Number of exacerbations per 52 weeks (exacerbation rates) (subgrouped by method used in control group)
Study or subgroup FeNO strategy Control strategy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Guideline driven
Pike 2013 28 3.71 (2.54) 35 3.2 (2.11) 3.3 % 0.51 [ -0.66, 1.68 ]
Szefler 2008 276 0.66 (1.41) 270 0.84 (1.4) 82.8 % -0.18 [ -0.42, 0.06 ]
Verini 2010 32 0.83 (0.98) 32 1.85 (1.34) 13.9 % -1.02 [ -1.60, -0.44 ]
Subtotal (95% CI) 336 337 100.0 % -0.27 [ -0.49, -0.06 ]
Heterogeneity: Chi2 = 8.79, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 2.50 (P = 0.012)
2 Other control
Petsky 2015 31 0.39 (0.71) 32 0.78 (1.07) 100.0 % -0.39 [ -0.84, 0.06 ]
Subtotal (95% CI) 31 32 100.0 % -0.39 [ -0.84, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.087)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Included studies definitions
Study ID Exacerbation
definition
FeNO strategy (FeNO
levels in ppb)
Symptom strategy Duration
de Jongste 2008 No definition provided
(OCS courses and hospi-
talisation data included
in exacerbation results)
In children aged 6 to 10
years:
< 20 and ≤ 60 symp-
tom score = step down/
discontinue
> 20 and≤ 60 symptom
score = increase
< 20 and > 60 symptom
Below range (< 10) = step
down/discontinue
In range (10 to 60) = no
change
Above range (>60) = step
up
30 weeks
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Table 1. Included studies definitions (Continued)
score = no change
> 20 and > 60 symptom
score = step up
In children aged > 10
years:
< 25 and ≤ 60 symp-
tom score = step down/
discontinue
> 25 and≤ 60 symptom
score = increase
< 25 and > 60 symptom
score = no change
> 25 and > 60 symptom
score = step up
Fritsch 2006 4 parameters:
OCS because of asthma
symptoms,
non-scheduled visit be-
cause of asthma
symptoms, > symptom
score to 2,
< FEV1 (in litres) > 10%
compared to
previous visit, or a com-
bination of these
≤ 20 and FEV1 ≥ 80%,
symptom score 0 or 1
and SABA
use < 6 = step down
≤ 20 and FEV1 < 80%
or symptoms score > 1 or
SABA
use ≥ 6 = step up
Participant on SABA on
demand only:
> 20 and FEV1 ≥ 80%,
symptom score 0 or 1
and SABA
use < 6 = step up
Participant on ICS:
> 20 and FEV1 ≥ 80%,
symptom score 0 or 1
and SABA
use < 6 = same step
> 20 and FEV1 < 80%
or symptoms score > 1 or
SABA
use ≥ 6 = step up
Austrian asthma guide-
lines:
FEV1 ≥ 80%, symptom
score 0 or 1 and SABA
use < 6 = step down
FEV1 < 80% or symp-
toms score > 1 or SABA
use ≥ 6 = step up
6 months
Peirsman 2014 As per GINA guidelines ≤ 20 and controlled =
step down
≤ 20 and partially con-
trolled consider LTRA
> 20 = step up
GINA guidelines 12 months
Petsky 2015 Respiratory events re-
quiring OCS
Elevated FeNO= step up
Low FeNO for 2 visits =
step down
Elevated FeNO defined
Asthma symptom diary
card
Score < 10 in previous
week = step down
12 months
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Table 1. Included studies definitions (Continued)
as:
≥ 10 with no positive
SPT
≥ 12with 1 positive SPT
≥ 20 with ≥ 2 positive
SPT
Score increased ≥ 15%
since previous week
= step up
Pijnenburg 2005 No definition provided
(OCS courses included
in results)
≤ 30 and symptom score
≤ 14 = step down
≤ 30 and symptom score
> 14 = no change
> 30, regardless of symp-
toms = step up
Symptom score ≤ 14
second time = step down
Symptom score ≤ 14
first time = no change
Symptom score > 14 =
step up
12 months
Pike 2013 ≥ 48 hours > asthma
symptoms or therapy or
< PEF (≥25%).
Mild: increase SABA
only
Moderate: requiring sys-
temic corticosteroids
Severe: requiring hospi-
talisations ≥ 8 hours
≤ 15 and well controlled
= step down
< 25 and poorly con-
trolled = LABA max-
imised
≥ 25 or FeNO doubled
from baseline = step up
If FeNO remained raised
after 2 x steps (SIGN/
BTS
steps) ICS not increased
again unless participant
poorly controlled
SIGN/BTS guidelines 12 months
Szefler 2008 Admissions to hospital,
unscheduled visits and
prednisone use for
asthma
NHLBI guidelines and
FeNO
≤ 20 and Level 1 = no
change
20.1 to 30 and Level 2 =
step up
30.1 to 40 and Level 3 =
2 steps
> 40 and Level 4 = 3
steps or 2 steps and OCS
course
NHLBI guidelines 46 weeks
Verini 2010 According to ATS/ERS
criteria and requiring
SABA.
At 6 month visit only:
< 12 = step down or no
change
> 12 = step up
As per GINA: 12 months
Voorend-van Bergen
2015
No definition provided
(OCS courses and hospi-
talisation data included
in exacerbation results)
If ACT ≥ 20 and:
FeNO < 25 = step down
FeNO≥ 25 to < 50 = no
change
ACT results:
< 20 = step up
≥ 20 = no change or step
down
12 months
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Table 1. Included studies definitions (Continued)
FeNO ≥ 50 = step up
If ACT < 20 and:
FeNO ≥ 25 = step up
FeNO < 25 = no change
ACT: Asthma Control Test; ATS: American Thoracic Society; BTS: British Thoracic Society; ERS: European Respiratory Society;
FeNO: fractional exhaled nitric oxide; FEV1: forced expiratory volume in first second; GINA: Global initiative for asthma; ICS:
inhaled corticosteroids; LTRA: leukotriene receptor antagonist; NHLBI: National Heart, Lung, and Blood Institute; OCS: oral
corticosteroids; ppb: parts per billion; SABA: short-acting beta2 agonist; SIGN: Scottish Intercollegiate Guidelines Network; SPT:
skin prick test.
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Hand-searches: core respiratory conference abstracts
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Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
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8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Nitric Oxide
#6 nitric* NEXT oxide*
#7 FeNO
#8 eNO
#9 “airway inflammation”
#10 “exhaled NO”
#11 biomarker*:ti,ab
#12 #5 or #6 or #7 or #8 or #9 or #10 or #11
#13 #4 and #12
[Note: in search line #1, MISC1 denotes the field in which the reference has been coded for condition, in this case, asthma]
Appendix 3. Search strategy to identify relevant trials for ClinicalTrials.gov and World Health
Organization trials portal
“exhaled nitric oxide” AND “asthma” AND “clinical trials”
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